| Title: |
Quality of life after transcatheter tricuspid valve repair: results from the Tri.FR trial |
| Authors: |
Istratoaie, Sabina; de Groote, Pascal; Karam, Nicole; Trochu, Jean-Noël; Leurent, Guillaume; Coisne, Augustin; Le Roux, Pierre‐yves; Ganivet, Anne; Bernard, Anne; Neylon, Antoinette; Pierrard, Romain; Leven, Florent; Picard, François; Piriou, Nicolas; Laperche, Thierry; Jouan, Jerome; Anselmi, Amedeo; Auffret, Vincent; Oger, Emmanuel; Donal, Erwan |
| Contributors: |
Centre Hospitalier Universitaire Rennes; Laboratoire Traitement du Signal et de l'Image (LTSI); Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM); Iuliu Haţieganu University of Medicine and Pharmacy of Cluj-Napoca = Universitatea de Medicină şi Farmacie Iuliu Haţieganu din Cluj-Napoca (UMF); Centre Hospitalier Régional Universitaire CHU Lille (CHRU Lille); Hôpital Européen Georges Pompidou APHP (HEGP); Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO); Institut du Thorax CHU Nantes (CHU Thorax); Médipôle Lyon-Villeurbanne (MLV); Centre Hospitalier Régional Universitaire de Tours (CHRU Tours); Membrane Signalling and Inflammation in reperfusion Injuries (ISCHEMIA); Université de Tours (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM); Institut Cardiovasculaire Paris Sud (ICPS); Hôpital Privé Jacques Cartier Massy; Centre Hospitalier Universitaire de Saint-Etienne CHU Saint-Etienne (CHU ST-E); Centre Hospitalier Régional Universitaire de Brest (CHRU Brest); Centre Hospitalier Universitaire de Bordeaux (CHU Bordeaux); Université de Bordeaux (UB); Centre cardiologique du Nord (CCN); CHU Limoges; Université de Rennes (UR); The trial has been funded by the French Ministry of Health (PHRC-N). The trial has been funded by the French Ministry of Health (PHRC-N). Abbott-structural provided the devices. We thank CHU Rennes research and innovation direction who supported the trial and the Cardiology Department and the contributors. Sophie Rushton-Smith (MedLink Healthcare Communications) provided editorial support on the final version of the manuscript. |
| Source: |
EISSN: 2055-5822 ; ESC Heart Failure ; https://hal.science/hal-05099066 ; ESC Heart Failure, 2025, 12 (4), pp.3053-3061. ⟨10.1002/ehf2.15327⟩ |
| Publisher Information: |
CCSD; Wiley |
| Publication Year: |
2025 |
| Collection: |
Université François-Rabelais de Tours: HAL |
| Subject Terms: |
Quality of life; Transcatheter valve; Tricuspid valve regurgitation; [SDV.IB]Life Sciences [q-bio]/Bioengineering; [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system |
| Description: |
International audience ; Aims: In the Tri.FR trial, tricuspid transcatheter edge-to-edge repair (T-TEER) reduced severity of tricuspid regurgitation (TR) and improved the composite clinical score, driven by patient-reported outcomes. The purpose of this study was to describe the longitudinal impact of T-TEER on different dimensions and items of quality of life compared with guideline-directed medical treatment (OMT) alone.Methods and results: Patients were randomized to T-TEER +OMT (n = 152) or OMT alone (n = 148). Health status was assessed at baseline, 6 weeks, 6 months, and 1 year using the Kansas City Cardiomyopathy Questionnaire (KCCQ) and the Minnesota Living with Heart Failure (MLHF) Questionnaire. Mixed effects linear regression analysed changes over time. Patients receiving T-TEER + OMT experienced a significant increase in KCCQ overall summary score (KCCQ-OS) at all time points: +17.0 points (95% confidence interval [CI] 13.1-21.5) at 6 weeks, +15.9 points (95% CI 11.2-20.6) at 6 months, and +18.7 points (95% CI 13.8-23.6) at 1 year. The mean between-group difference in KCCQ-OS was +10.3 points (95% CI 5.6-15.0) in favour of T-TEER + OMT, evident at 6 weeks and sustained for 1 year. Similarly, MLHF total scores improved significantly in the T-TEER group (mean between-group difference -8.61 points, 95% CI -12.6 to -4.6), including physical (-3.9, 95% CI -5.9 to -1.9) and emotional (-2.2, 95% CI -3.4 to -1.0) subscales.Conclusions: Compared with OMT alone, T-TEER resulted in substantial, multidimensional, and sustained improvements in patient-reported quality of life. These findings reinforce the value of T-TEER in managing severe symptomatic TR. |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| Relation: |
info:eu-repo/semantics/altIdentifier/pmid/40387042; PUBMED: 40387042 |
| DOI: |
10.1002/ehf2.15327 |
| Availability: |
https://hal.science/hal-05099066; https://hal.science/hal-05099066v1/document; https://hal.science/hal-05099066v1/file/ESC%20Heart%20Failure%20-%202025%20-%20Istratoaie%20-%20Quality%20of%20life%20after%20transcatheter%20tricuspid%20valve%20repair%20results%20from%20the%20Tri%20FR.pdf; https://doi.org/10.1002/ehf2.15327 |
| Rights: |
https://creativecommons.org/licenses/by-nc/4.0/ ; info:eu-repo/semantics/OpenAccess |
| Accession Number: |
edsbas.59FF08D2 |
| Database: |
BASE |